1. Basilar artery occlusion management: An international survey of middle versus high-income countries.
- Author
-
Drumm B, Herning A, Klein P, Raymond J, Abdalkader M, Huo X, Chen Y, Siegler JE, Peacock M, Schonewille WJ, Liu X, Hu W, Ji X, Li C, Alemseged F, Liu L, Nagel S, Strbian D, Rebello LC, Yaghi S, Qureshi MM, Fischer U, Tsivgoulis G, Kaesmacher J, Yamagami H, Puetz V, Sylaja PN, Marto JP, Sacco S, Kristoffersen ES, Demeestere J, Conforto AB, Meyer L, Kaiser DPO, Reiff T, Aydin K, Romoli M, Diana F, Lobotesis K, Roi D, Masoud HE, Ma A, Mohammaden MH, Doheim MF, Zhu Y, Sang H, Sun D, Ton MD, Raynald, Li F, Lapergue B, Hanning U, Yang Q, Lee JS, Thomalla G, Yang P, Liu J, Campbell BCV, Chen HS, Zaidat OO, Qiu Z, Nogueira RG, Miao Z, Nguyen TN, and Banerjee S
- Subjects
- Humans, Thrombectomy, Surveys and Questionnaires, Practice Patterns, Physicians' statistics & numerical data, Female, Male, Endovascular Procedures, Vertebrobasilar Insufficiency therapy, Vertebrobasilar Insufficiency diagnostic imaging, Vertebrobasilar Insufficiency surgery, Developed Countries
- Abstract
Background and Purpose: Two early basilar artery occlusion (BAO) randomized controlled trials (RCTs) did not establish the superiority of endovascular thrombectomy (EVT) over medical management. Yet many providers continued to recommend EVT. The goal of the present article is to compare physicians' diagnostic and management strategies of BAO among middle-income and high-income countries (MICs and HICs, respectively)., Methods: We conducted an international survey from January to March 2022 regarding management strategies in acute BAO, to examine clinical and imaging parameters influencing clinician management of patients with BAO. We compared responses between physicians from HIC and MIC., Results: Among the 1245 respondents from 73 countries, 799 (64.2%) were from HIC, with the remaining 393 (31.6%) from MIC. Most respondents perceived that EVT was superior to medical management for acute BAO, but more so in respondents from HIC (98.0% vs. 94.2%, p < 0.01). MIC respondents were more likely to believe further RCTs were warranted (91.6% vs. 74.0%, p < 0.01) and were more likely to find it acceptable to enroll any patient who met a trial's criteria in the standard medical treatment arm (58.8% vs. 38.5%, p < 0.01)., Conclusions: In an area where clinical equipoise was called into question despite the lack of RCT evidence, we found that respondents from MIC were more likely to express willingness to enroll patients with BAO in an RCT than their HIC counterparts., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Alemseged reported research grants from Medical Research Future Fund, Australian Heart Foundation, Sylvia & Charles Viertel Charitable Foundation. Dr Fischer reported research grants from Medtronic; consultant for Medtronic, Stryker, CSL Behring; advisory board for Alexion/Portola. Dr Kaesmacher reported grants from the Swiss Academy of Medical Sciences/Bangerter Foundation, Swiss Stroke Society, Clinical Trials Unit Bern, and the Swiss National Science Foundation. Dr Nagel reported consultancy for Brainomix, speaker bureaus with Boehringer Ingelheim and Pfizer. Dr Nguyen reported research support from Medtronic and SVIN. Dr Puetz reported fees as lecturer for Daiichi Sankyo. Dr Sacco reported research grants from Novartis and Uriach; fees for advisor or speaker from Abbott, Allergan-Abbvie, AstraZeneca, Lilly, Lundbeck, Novartis, Novo Nordisk, Pfizer, Teva. Dr Siegler reported consulting from Ceribell and speakers’ bureau with AstraZeneca. Dr Thomalla reported fees as a consultant from Acandis, Alexion, Amarin, Bayer, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Portola, and Stryker. Dr Yamagami reported research grants from Bristol-Myers Squibb, lecturer’s fees from Bayer, Daiichi-Sankyo, Stryker, Bristol-Myers Squib; advisory boards for Daiichi-Sankyo. Dr Banerjee reported consultancy for RapidAI. Dr Marto reports consulting fees from Amicus Therapeutics and Boehringer Ingelheim; speaker fees from Boehringer Ingelheim. Dr Kaiser reported grants from the Joachim Herz Foundation and the Else Kröner Fresenius Center for Digital Health.
- Published
- 2024
- Full Text
- View/download PDF